Quest Diagnostics Lifts Outlook On Strong Earnings Call

Quest Diagnostics ((DGX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Quest Diagnostics struck an optimistic tone on its latest earnings call, pointing to strong growth in volumes, revenue, and earnings while leaning on productivity gains from automation and AI. Management acknowledged several near-term headwinds, but emphasized that robust demand, expanding partnerships, and higher guidance leave the company on a firmer growth trajectory than a year ago.

Strong Revenue Growth

Quest reported consolidated revenues of $2.9 billion in the first quarter, a 9.2% increase versus the prior year as demand broadened across its portfolio. Organic revenue climbed 9.0%, underlining that most of the growth is coming from the core business rather than acquisitions or one-off items.

Volume Expansion

Total testing requisitions jumped 10.9% year over year, with organic volume up 10.8%, signaling healthy underlying demand. Roughly 7 percentage points of that organic volume came from the ramp-up of collaborations with Fresenius Medical Care and Corewell Health, leaving still solid 3.8% growth excluding these relationships.

Improved Profitability and EPS

Operating performance strengthened as reported operating income rose to $399 million, or 13.8% of revenue, from $346 million and 13.0% a year earlier. Adjusted EPS increased about 13% to $2.50, reflecting better margins and scale benefits despite cost pressures and business mix changes.

Consumer Channel Momentum

The company’s direct-to-consumer business, accessible through questhealth.com, continued to gain traction with growth in the high‑20s percent range. Consumer partnerships posted even faster increases, supported by high repeat usage and growing demand for new offerings such as Elite health profiles and autoimmune and hormone tests.

Advanced Diagnostics Outperformance

Advanced diagnostics remained a standout, delivering double-digit revenue growth across brain health, cardiometabolic and endocrine testing, autoimmune disease, oncology, and women’s health. Use of the AD‑Detect Alzheimer’s test more than doubled, while new cardiovascular guidelines fueled rising orders for Lp(a) and ApoB assays.

Operational Productivity via AI and Automation

Quest highlighted tangible productivity gains from automation and AI, including about a 40% efficiency improvement among customer service agents using AI-based triage tools. Its Quest AI Companion has already logged roughly 350,000 patient interactions, and the broader Invigorate initiative remains targeted at generating around 3% annual cost savings.

Strategic Collaborations and Capacity Investments

Strategic collaborations with Corewell Health and Fresenius Medical Care are emerging as key growth engines, materially contributing to volume growth and broadening Quest’s reach. To support rising demand, the company is investing heavily in lab capacity, including a state‑of‑the‑art facility in Southeast Michigan and additional esoteric testing infrastructure.

Revenue per Requisition Mix Shift

Revenue per requisition fell 1.3% as the company processed a larger share of lower-priced routine tests tied to the Fresenius and Corewell partnerships. Excluding those collaborations, revenue per requisition increased about 2.5%, suggesting the underlying test mix remains positive even as newer relationships temporarily pressure averages.

Cash from Operations Decline in Q1

Cash from operations slipped to $278 million from $314 million in the prior-year quarter, even as earnings improved. Management attributed the decline mainly to timing of cash receipts and disbursements and higher bonus payouts, rather than to structural weakness in the business.

Near-Term Cost Pressures

Wage inflation, severe weather, and fuel costs presented measurable headwinds, shaving some of the benefit from higher volume and efficiency gains. Management estimated weather reduced revenue by about $9 million and operating income by around $7 million, while elevated fuel costs are expected to weigh on EPS by roughly $0.05 to $0.07 this year.

Project Nova Investment Dilution

Project Nova, a major strategic initiative, will pressure near-term earnings even as it aims to enhance long-term capabilities and growth. The company expects the project to dilute 2026 EPS by about $0.25, with more than 60% of related spending now scheduled for the second half of that year.

PAMA and Medicare Rate Uncertainty

Management flagged ongoing uncertainty around future Medicare reimbursement under PAMA and potential legislative changes. While some outcomes could be neutral or even positive, depending on how data are collected and whether new laws are passed, the company acknowledged that visibility into 2027 rates remains limited.

Regulatory and Enforcement Scrutiny

Broader fraud, waste, and abuse initiatives by federal agencies are raising regulatory scrutiny across the lab industry. Quest emphasized that its exposure to the specific test categories driving Medicare spending spikes is minimal, but still noted that the overall enforcement environment is becoming more demanding for all players.

Mix-Related Margin Effects from New Collaborations

The large Fresenius and Corewell contracts are initially diluting margins because they skew toward routine tests with lower revenue per requisition. Management expects profitability from these relationships to improve as volumes mature and efficiency ramps, but conceded that mix effects will weigh on margins in the near term.

Upgraded Guidance and Forward Outlook

Quest raised its full-year 2026 outlook, now projecting revenue between $11.78 billion and $11.90 billion, or growth of roughly 6.8% to 7.8%. The company sees reported EPS of $9.58 to $9.78 and adjusted EPS of $10.63 to $10.83, with expanding operating margins, about $1.75 billion of operating cash flow, and $550 million in capital spending, all while absorbing fuel and Project Nova headwinds.

Quest Diagnostics’ latest call painted a picture of a company balancing short-term cost and mix challenges against robust demand, rising productivity, and expanding partnerships. With higher guidance, strong advanced diagnostics momentum, and ongoing investment in capacity and technology, management is signaling confidence that the growth story has meaningful room to run despite regulatory and reimbursement uncertainties.